Box 1: Targeting Pericytes to Overcome Resistance to VEGF-Targeted Therapy

Box 1: Targeting pericytes to overcome resistance to VEGF-targeted therapy

Mural pericytes stabilize nascent vessels by inhibiting endothelial proliferation and migration, promoting endothelial survival, tightening the endothelial barrier via deposition of a common basement membrane and formation of junctions, and controlling, through vasoregulation, vessel function and perfusion.7,S1 Members of the PDGF family control the recruitment of mural cells around naked endothelial channels.S2 This family consists of five ligands (PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC and PDGF-DD), binding to three receptor dimers (PDGFR, PDGFRß and PDGFRß).S3 Certain family members stimulate tumor angiogenesis and growth through effects on endothelial or malignant cells, and increase interstitial tumor pressure via effects on myofibroblasts; indirect effects also rely on the upregulation of angiogenic factors.S4

During normal vessel branching, endothelial tip cells release PDGF-BB to recruit PDGFRß+ mural cells; this is also the case in inflamed tissues, when cytokines such as TNF upregulate PDGF-BB.S5 Loss of PDGF-BB or PDGFRß in development does not affect microvessel density, length or number of branch points, but the absence of pericytes correlates with EC hyperplasia, increased capillary diameter, abnormal EC shape and ultrastructure, changed distribution of junctional proteins, and morphological signs of increased transendothelial permeability;S6 similar findings were observed in the ischemic retina.S7 Tumor-cell production of PDGF-AA recruits PDGFR+ myofibroblasts, which produce VEGF to rescue angiogenesis in VEGF-deficient tumors.S8VEGF(R) inhibitor refractory tumors can overcome inhibition of VEGF-driven angiogenesis through upregulation of PDGF-C, a known angiogenic factor.S9

Unlike mature vessels in healthy organs, vessels in tumors are more immature and surrounded by fewer pericytes, which contributes to their “vessel abnormalization”. Genetic studies show that immature, pericyte-poor tumor vessels are more sensitive to VEGF withdrawal.S10 Hence, it was postulated that strategies to deprive the tumor vasculature of pericytes would increase its sensitivity towards VEGF-targeted therapy. Indeed, pharmacological inhibition, using multi-targeted tyrosine kinase inhibitors, of PDGFRß signaling in tumor pericytes amplifies VEGFR inhibitors in suppressing tumor growth.S1 Similar findings were obtained with neutralizing antibodies against VEGFR2 (VEGFR2) and PDGFRß (PDGFRß).S11Combination therapy with a PDGRß-trap and VEFR2-trap yielded a modest additive effect, but only when a submaximal dose of the VEGFR-trap was used.S12 Contradictory results have been reported when PDGF-BB is overexpressed in experimental tumors; while this leads to increased pericyte coverage of tumor vessels in all cases, tumor growth was either increased (presumably because malignant cells express PDGFRß and proliferate upon autocrine overproduction of PDGF-BB)S4 or reduced (presumably because, in this case, excess pericyte recruitment inhibits EC proliferation and vascular density).S13 Deprivation of tumor vessels from pericytes may cause harm by tightening the EC barrier, pericytes impede tumor cell intravasation and metastasis, explaining why inhibition of PDGFs or othter pericyte recruitment signals favoured metastasis.S14

Box 2: Targeting leukocytes to overcome resistance to VEGF-targeted therapy

Preclinical evidence indicates that tumor infiltration of myeloid cells, such as CD11b+Gr1+ myeloid cells and F4/80+ macrophages, confers refractoriness of tumors to VEGF(R) inhibitors.74,S15,S16 Indeed, depletion of F4/80+ macrophages from mice, bearing tumors that are refractory to VEGFR2 restored their sensitivity to this inhibitor.74 Likewise, depletion of CD11b+Gr1+ myeloid cells in preclinical models sensitized tumors to VEGF therapy, while, conversely, infusion of these cells in tumors, sensitive to VEGF therapy, rendered these tumors refractory to VEGF inhibition.S15 It is somewhat surprising that VEGF(R) inhibitors fail to inhibit the recruitment of angiocompetent VEGFR1+ myeloid cells, since VEGF chemoattracts VEGFR1-expressing myeloid cells.68 These infiltrating inflammatory cells promote tumor angiogenesis by secreting a myriad of growth factors such as PlGF, VEGF-C, FGFs, PDGFs, angiopoietins, chemokines, proteinases and many other molecules;S17 they also stimulate tumor growth by suppressing the immune response against malignant cells.S16

Recent studies revealed that Bv8 promotes the recruitment of resistance-conferring angiogenic myeloid cells, and stimulates angiogenesis directly.S18Bv8 is a mitogen for a subset of ECs and haematopoietic progenitors, besides having other non-vascular activities.S18,S19 This protein is upregulated by G-CSF (often expressed by tumor and stromal cells), but also enhances G-CSF induced recruitment of resistance-conferring CD11b+Gr1+ myeloid cells from the bone marrow into tumors.S15 Tumors that are refractory to VEGF spontaneously recruit CD11b+Gr1+ myeloid cells, while others do this only in response to VEGF-targeted therapy.S16 Bv8 contributes to the angiogenic switch in early but not in advanced stages of tumor growth in the Rip-Tag model of pancreatic insulinoma.S20 Anti-Bv8 (Bv8) antibodies impede tumor infiltration of CD11b+Gr1+ cells, and inhibit the growth and angiogenesis of tumors, not only of those that are sensitive, but also those that are resistant to VEGF-inhibitor therapy. Combined delivery of Bv8 with VEGF elicits an additive anti-tumor effect in implanted tumor models, but not in the pancreatic Rip-Tag tumor model.S20,S21 Consistent with findings that chemotherapy induces mobilization of hematopoietic cells from the bone marrow, and that cytotoxic tumor necrosis upregulate chemokines such as G-CSF with subsequent generation of neutrophils, combined delivery of Bv8 with cytotoxic agents enhanced tumor growth inhibition.S21

References

S1.Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E. & Hanahan, D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest.111, 1287–1295 (2003).

S2.Furuhashi, M. et al. Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Cancer Res.64, 2725–2733 (2004).

S3.Andrae, J., Gallini, R. & Betsholtz, C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev.22, 1276–1312 (2008).

S4.Guo, P. et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am. J. Pathol.162, 1083–1093 (2003).

S5.Sainson, R.C. et al. TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype. Blood111, 4997–5007 (2008).

S6.Hellstrom, M. et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J. Cell. Biol.153, 543–553 (2001).

S7.Wilkinson-Berka, J.L. et al. Inhibition of platelet-derived growth factor promotes pericyte loss and angiogenesis in ischemic retinopathy. Am. J. Pathol.164, 1263–1273 (2004).

S8.Dong, J. et al. VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J.23, 2800–2810 (2004).

S9.Crawford, Y. et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell15, 21–34 (2009).

S10.Benjamin, L.E., Golijanin, D., Itin, A., Pode, D. & Keshet, E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest.103, 159–165 (1999).

S11.Shen, J. et al. An antibody directed against PDGF receptor beta enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody. Biochem. Biophys. Res. Commun.357, 1142–1147 (2007).

S12.Kuhnert, F. et al. Soluble receptor-mediated selective inhibition of VEGFR and PDGFRbeta signaling during physiologic and tumor angiogenesis. Proc. Natl. Acad. Sci. USA105, 10185–10190 (2008).

S13.McCarty, M.F. et al. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. J. Clin. Invest.117, 2114–2122 (2007).

S14.Gerhardt, H. & Semb, H. Pericytes: gatekeepers in tumour cell metastasis? J. Mol. Med.86, 135–144 (2008).

S15.Shojaei, F. et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol.25, 911–920 (2007).

S16.Shojaei, F. & Ferrara, N. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resist. Updat.11, 219–230 (2008).

S17.Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature454, 436–444 (2008).

S18.LeCouter, J. et al. The endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis: Localization of Bv8 receptors to endothelial cells. Proc. Natl. Acad. Sci. USA100, 2685–2690 (2003).

S19.LeCouter, J., Zlot, C., Tejada, M., Peale, F. & Ferrara, N. Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization. Proc. Natl. Acad. Sci. USA101, 16813–16818 (2004).

S20.Shojaei, F., Singh, M., Thompson, J.D. & Ferrara, N. Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc. Natl. Acad. Sci. USA105, 2640–2645 (2008).

S21. Shojaei, F. et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature450, 825–831 (2007).